CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Clearside Biomedical, Inc. - CLSD CFD

0.8525
3.05%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0092
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Clearside Biomedical Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.8273
Open* 0.8173
1-Year Change* -27.67%
Day's Range* 0.8173 - 0.8525
52 wk Range 0.85-1.85
Average Volume (10 days) 89.50K
Average Volume (3 months) 2.60M
Market Cap 52.73M
P/E Ratio -100.00K
Shares Outstanding 62.03M
Revenue 1.62M
EPS -0.59
Dividend (Yield %) N/A
Beta 2.17
Next Earnings Date Nov 6, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 22, 2023 0.8525 0.0352 4.31% 0.8173 0.8543 0.8173
Sep 21, 2023 0.8273 0.0100 1.22% 0.8173 0.8283 0.8173
Sep 20, 2023 0.8273 0.0000 0.00% 0.8273 0.8463 0.8273
Sep 19, 2023 0.8279 0.0106 1.30% 0.8173 0.8470 0.8173
Sep 18, 2023 0.8298 0.0025 0.30% 0.8273 0.8473 0.8223
Sep 15, 2023 0.8473 0.0000 0.00% 0.8473 0.8642 0.8373
Sep 14, 2023 0.8430 -0.0043 -0.51% 0.8473 0.8683 0.8405
Sep 13, 2023 0.8496 -0.0097 -1.13% 0.8593 0.8673 0.8473
Sep 12, 2023 0.8537 -0.0136 -1.57% 0.8673 0.8773 0.8503
Sep 11, 2023 0.8673 0.0050 0.58% 0.8623 0.8873 0.8504
Sep 8, 2023 0.8533 0.0060 0.71% 0.8473 0.8673 0.8323
Sep 7, 2023 0.8473 0.0000 0.00% 0.8473 0.8548 0.8473
Sep 6, 2023 0.8499 -0.0374 -4.22% 0.8873 0.8973 0.8473
Sep 5, 2023 0.8593 -0.0394 -4.38% 0.8987 0.9273 0.8473
Sep 1, 2023 0.9073 0.0100 1.11% 0.8973 0.9283 0.8973
Aug 31, 2023 0.9173 0.0020 0.22% 0.9153 0.9283 0.9123
Aug 30, 2023 0.9202 -0.0071 -0.77% 0.9273 0.9420 0.9202
Aug 29, 2023 0.9190 0.0017 0.19% 0.9173 0.9424 0.9153
Aug 28, 2023 0.9173 -0.0150 -1.61% 0.9323 0.9373 0.9173
Aug 25, 2023 0.9373 0.0200 2.18% 0.9173 0.9470 0.9173

Clearside Biomedical, Inc. Events

Time (UTC) Country Event
Monday, November 6, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Clearside Biomedical Inc Earnings Release
Q3 2023 Clearside Biomedical Inc Earnings Release

Forecast

-

Previous

-
Thursday, March 7, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Clearside Biomedical Inc Earnings Release
Q4 2023 Clearside Biomedical Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1.327 29.575 7.894 2.173 0.03
Revenue 1.327 29.575 7.894 2.173 0.03
Total Operating Expense 30.935 29.199 25.829 32.477 82.975
Selling/General/Admin. Expenses, Total 11.77 11.665 10.756 16.819 14.684
Research & Development 19.63 18.537 15.073 15.658 68.291
Operating Income -29.608 0.376 -17.935 -30.304 -82.945
Other, Net -3.339 0 -0.275 -0.466 0.127
Net Income Before Taxes -32.947 0.376 -18.21 -30.77 -82.818
Net Income After Taxes -32.947 0.376 -18.21 -30.77 -82.818
Net Income Before Extra. Items -32.947 0.376 -18.21 -30.77 -82.818
Net Income -32.947 0.376 -18.21 -30.77 -82.818
Income Available to Common Excl. Extra. Items -32.947 0.376 -18.21 -30.77 -82.818
Income Available to Common Incl. Extra. Items -32.947 0.376 -18.21 -30.77 -82.818
Diluted Net Income -32.947 0.376 -18.21 -30.77 -82.818
Diluted Weighted Average Shares 60.2049 59.9066 46.5065 38.1708 30.7336
Diluted EPS Excluding Extraordinary Items -0.54725 0.00628 -0.39156 -0.80611 -2.69471
Diluted Normalized EPS -0.55836 -0.01047 -0.39156 -0.80611 -2.69471
Total Extraordinary Items
Unusual Expense (Income) -0.669 -1.003
Cost of Revenue, Total 0.204
Gross Profit 1.123
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 1.018 0.004 0.33 0.266 0.384
Revenue 1.018 0.004 0.33 0.266 0.384
Total Operating Expense 7.83 7.117 7.951 6.796 8.197
Selling/General/Admin. Expenses, Total 3.127 3.158 3.169 2.353 2.791
Research & Development 4.948 4.451 5.027 4.637 5.43
Unusual Expense (Income) -0.458 -0.492 -0.449 -0.194 -0.024
Operating Income -6.812 -7.113 -7.621 -6.53 -7.813
Other, Net -2.294 -2.167 -2.042 -1.297
Net Income Before Taxes -9.106 -9.28 -9.663 -7.827 -7.813
Net Income After Taxes -9.106 -9.28 -9.663 -7.827 -7.813
Net Income Before Extra. Items -9.106 -9.28 -9.663 -7.827 -7.813
Net Income -9.106 -9.28 -9.663 -7.827 -7.813
Income Available to Common Excl. Extra. Items -9.106 -9.28 -9.663 -7.827 -7.813
Income Available to Common Incl. Extra. Items -9.106 -9.28 -9.663 -7.827 -7.813
Diluted Net Income -9.106 -9.28 -9.663 -7.827 -7.813
Diluted Weighted Average Shares 61.6545 61.1695 60.415 60.1885 60.1503
Diluted EPS Excluding Extraordinary Items -0.14769 -0.15171 -0.15994 -0.13004 -0.12989
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.15512 -0.15975 -0.16738 -0.13326 -0.13029
Cost of Revenue, Total 0.213 0.204
Gross Profit 0.805 0.126
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 49.401 42.136 18.118 25.219 42.944
Cash and Short Term Investments 48.258 30.436 17.287 22.595 40.878
Cash & Equivalents 48.258 30.436 17.287 22.595 8.043
Short Term Investments 0 32.835
Prepaid Expenses 0.704 0.921 0.722 1.139 2.049
Other Current Assets, Total 0.439 0.779 0.109 1.485 0.017
Total Assets 51.303 42.903 19.322 26.776 44.12
Property/Plant/Equipment, Total - Net 1.872 0.607 0.944 1.197 0.79
Property/Plant/Equipment, Total - Gross 2.725 1.562 1.721 1.794 1.199
Accumulated Depreciation, Total -0.853 -0.955 -0.777 -0.597 -0.409
Other Long Term Assets, Total 0.03 0.16 0.26 0.36 0.386
Total Current Liabilities 5.783 4.64 9.943 10.903 10.476
Accounts Payable 1.05 0.941 1.997 1.28 6.869
Accrued Expenses 4.528 3.699 1.955 3.29 2.923
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.205 0 5 5 0.128
Total Liabilities 40.696 4.928 10.559 15.619 20.5
Total Long Term Debt 0 0 0 3.819 9.419
Long Term Debt 0 3.819 9.419
Other Liabilities, Total 34.913 0.288 0.616 0.897 0.605
Total Equity 10.607 37.975 8.763 11.157 23.62
Redeemable Preferred Stock 0 0
Common Stock 0.061 0.06 0.052 0.044 0.032
Additional Paid-In Capital 298.984 293.406 264.578 248.77 230.475
Retained Earnings (Accumulated Deficit) -288.438 -255.491 -255.867 -237.657 -206.887
Other Equity, Total 0
Total Liabilities & Shareholders’ Equity 51.303 42.903 19.322 26.776 44.12
Total Common Shares Outstanding 60.6398 59.7229 51.8609 44.4134 32.1192
Current Port. of LT Debt/Capital Leases 0 0.991 1.333 0.556
Total Receivables, Net 0 10
Accounts Receivable - Trade, Net 0 10
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 42.567 49.401 54.862 29.989 35.274
Cash and Short Term Investments 41.419 48.258 53.381 29.033 34.372
Cash & Equivalents 41.419 48.258 53.381 29.033 34.372
Prepaid Expenses 0.762 0.704 1.047 0.439 0.563
Other Current Assets, Total 0.386 0.439 0.311 0.394 0.339
Total Assets 44.695 51.303 55.685 30.746 36.059
Property/Plant/Equipment, Total - Net 2.098 1.872 0.663 0.597 0.625
Property/Plant/Equipment, Total - Gross 2.966 2.725 1.741 1.636 1.626
Accumulated Depreciation, Total -0.868 -0.853 -1.078 -1.039 -1.001
Other Long Term Assets, Total 0.03 0.03 0.16 0.16 0.16
Total Current Liabilities 4.984 5.783 5.204 5.393 4.156
Accounts Payable 1.594 1.05 1.739 2.644 1.396
Accrued Expenses 3.11 4.528 3.352 2.749 2.562
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 0.28 0.205 0.113 0.198
Total Liabilities 41.995 40.696 37.139 5.498 4.356
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 37.011 34.913 31.935 0.105 0.2
Total Equity 2.7 10.607 18.546 25.248 31.703
Common Stock 0.061 0.061 0.06 0.06 0.06
Additional Paid-In Capital 300.357 298.984 297.261 296.136 294.778
Retained Earnings (Accumulated Deficit) -297.718 -288.438 -278.775 -270.948 -263.135
Total Liabilities & Shareholders’ Equity 44.695 51.303 55.685 30.746 36.059
Total Common Shares Outstanding 61.3643 60.6398 60.1907 60.1504 60.1476
Redeemable Preferred Stock
Total Receivables, Net 0 0.123 0.123 0
Accounts Receivable - Trade, Net 0 0.123 0.123 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -32.947 0.376 -18.21 -30.77 -82.818
Cash From Operating Activities -13.365 -10.733 -13.12 -27.068 -79.2
Cash From Operating Activities 0.145 0.178 0.18 0.211 0.189
Non-Cash Items 8.201 4.056 3.788 4.79 4.303
Cash Interest Paid 0 0 0.524 0.843 0.751
Changes in Working Capital 11.236 -15.343 1.122 -1.299 -0.874
Cash From Investing Activities -0.246 0 -0.055 32.925 -3.76
Capital Expenditures -0.246 0 -0.055 -0.025 -0.088
Other Investing Cash Flow Items, Total 0 32.95 -3.672
Cash From Financing Activities 31.333 23.782 7.867 8.695 81.779
Issuance (Retirement) of Stock, Net 0.695 23.782 12.216 13.695 80.079
Issuance (Retirement) of Debt, Net 0 0 -4.349 -5 1.7
Net Change in Cash 17.722 13.049 -5.308 14.552 -1.181
Financing Cash Flow Items 30.638
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.28 -32.947 -23.284 -15.457 -7.644
Cash From Operating Activities -7.216 -13.365 -7.758 -1.572 3.871
Cash From Operating Activities 0.015 0.145 0.123 0.084 0.046
Non-Cash Items 3.208 8.201 5.032 2.661 1.307
Changes in Working Capital -1.159 11.236 10.371 11.14 10.162
Cash From Investing Activities -0.115 -0.246 -0.155 0 0
Capital Expenditures -0.115 -0.246 -0.155
Cash From Financing Activities 0.332 31.333 30.758 0.069 0.065
Issuance (Retirement) of Stock, Net 0.332 0.695 0.12 0.069 0.065
Net Change in Cash -6.999 17.722 22.845 -1.503 3.936
Issuance (Retirement) of Debt, Net 0
Other Investing Cash Flow Items, Total 0 0
Financing Cash Flow Items 30.638 30.638

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Clearside Biomedical, Inc. Company profile

About Clearside Biomedical Inc

Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Its proprietary suprachoroidal space (SCS) microinjector targeting SCS offers access to the macula, retina and choroid where sight-threatening disease often occurs. The SCS injection platform is an inherently flexible, in-office, non-surgical procedure intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations. The Company’s suprachoroidal injection platform is a patented approach for delivering pharmacotherapy to the back of the eye through SCS. The Company’s lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Clearside Biomedical Inc revenues increased from $7.9M to $29.6M. Net income totaled $376K vs. loss of $18.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Other expense decrease from $275K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to $0.01.

Industry: Bio Therapeutic Drugs

900 North Point Parkway
Suite 200
ALPHARETTA
GEORGIA 30005
US

Income Statement

  • Annual
  • Quarterly

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

XRP/USD

0.52 Price
+0.220% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

US100

14,710.90 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

26,634.85 Price
-0.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

ETH/USD

1,597.00 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading